Hildur Helgadottir retweeted
Welcome to read the Editor´s Choice in May!
➡️ Perioperative immune checkpoint inhibitor therapy across tumors
➡️ Insights and shared lessons from a rapidly evolving field
🔗doi.org/10.1111/joim.70073
👉 Also, read the May issue! onlinelibrary.wiley.com/toc/…
#immunotherapy #oncology
Hildur Helgadottir retweeted
New review to read! Perioperative immune checkpoint inhibitor therapy across tumors.
➡️ Insights and shared lessons from a rapidly evolving field.
➡️ Major evolution in curative-intent oncology.
🔗 doi.org/10.1111/joim.70073
#adjuvanttherapy #immunecheckpointinhibitors #neoplasms
Hildur Helgadottir retweeted
Read more! Immunotherapy used earlier in several cancer types. New article! news.ki.se/immunotherapy-use…
#immunotherapy #oncology
Hildur Helgadottir retweeted
Still no benefit in OS after the introduction of adjuvant immunotherapy for patients with melanoma in Sweden. A nationwide registry-based study published in European Journal of Cancer ejcancer.com/article/S0959-8…
Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study - European Journal of Cancer ejcancer.com/article/S0959-8…
36
Hildur Helgadottir retweeted
🩺 Real-world #melanoma data suggest flipping nivolumab/ipilimumab doses may lead to longer survival with fewer toxicities compared with standard dosing. #Immunotherapy
👩⚕️ @HildurHelg | @JNCI_Now
Read the article: ascopost.com/news/december-2…
Evaluation of the flipped dose NIVO3+IPI1 in patients with advanced unresectable melanoma academic.oup.com/jnci/articl…
42
Hildur Helgadottir retweeted
Lower doses of immunotherapy for advanced melanoma demonstrate higher response rates, longer survival, and fewer #SeriousSideEffects compared to traditional dosing, according to recent clinical data. @JNCI_Now doi.org/hbdtx5 medicalxpress.com/news/2025-…
Desmoplastic melanoma in Sweden in 2009–2022: A population‐based registry study demonstrating distinctive tumour characteristics, incidence and survival trends - Girmay - Journal of the European Academy of Dermatology and Venereology - Wiley Online Library onlinelibrary.wiley.com/doi/…
1
240
Hildur Helgadottir retweeted
#ESMO24: Questions remain on optimal #AdjuvantTherapy for advanced #melanoma. OS trial data are not yet available & #RealWorld data suggest that surrogate endpoints may not translate into OS benefit in clinical practice @TeresaSAmaral #ESMODailyReporter
📌ow.ly/51Cs50TnILV
Hildur Helgadottir retweeted
Replying to @HildurHelg
@HildurHelg presents out Swedish data showing no OS benefit with adjuvant immunotherapy for stage III melanoma. #ESMO24
Hildur Helgadottir retweeted
Swedish cohort study reveals declining melanoma incidence and mortality in 30-49 year-olds, hinting at potential future population-wide decrease. Increased sun protection awareness may be a contributing factor, but further research is needed. ja.ma/4ggunxt
Hildur Helgadottir retweeted
The risk of skin cancer for adults under the age of 50 is now decreasing for the first time in Sweden, according to a study published in @JAMADerm.
Research by @HildurHelg et al.
news.ki.se/breaking-the-tren…
Does the Germline Genome Encode for the Invasiveness of a Cutaneous Melanoma?
A thought provoking question up for discussion in an Editorial in current JAMA Derm on GWAS article by Ingold et al.
jamanetwork.com/journals/jam…
1
4
187
Such a pleasure to host Professor Michael Atkins here at Karolinska Comprehensive Cancer Center. Excellent presentation and very interesting discussion on burning melanoma topics
8
429
Come and work with us in the melanoma research team at Karolinska Comprehensive Cancer Center. We are looking to hire a postdoc researcher in the lab
ki.varbi.com/what:job/jobID:…





















